Adlai Nortye to Work With Eli Lilly, Merck on Trial for Cancer Treatment
Kelly Cloonan
Adlai Nortye Group inked agreements for Eli Lilly and Merck to work on a trial for its AN4035, which is in development to treat certain types of tumors.
The biotechnology company said Thursday the clinical-trial collaboration-and-supply agreements will support its Phase 1 trial evaluating AN4035 both as monotherapy and in combination with cetuximab.
Lilly will supply cetuximab at no cost for the U.S. clinical trial sites, and Merck will supply cetuximab at no cost for the Australia and China clinical trial sites, Adlai Nortye said.
Adlai Nortye is the sponsor of the trial, it said.
The trial aims to evaluate AN4035 in patients with CEACAM5-enriched, RAS-addicted solid tumors. CEACAM5 is overexpressed in colorectal, pancreatic and lung cancers, which are tumor types that frequently harbor RAS, or rat sarcoma, mutations, Adlai Nortye said.
Adlai Nortye shares were up 2.9% to $11.20 in premarket trading.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
October 15, 2026 09:06 ET (13:06 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
What’s Ahead for Stocks This Quarter—and Where to Invest
United States